Relative Bioavailability Following Single Oral Administration of 200 mg of BI 44370 During and Between Migraine Attacks in Male and Female Migraine Patients. An Open-label, Fixed-sequence, Two-period Study With Intraindividual Comparison
Latest Information Update: 24 Apr 2014
At a glance
- Drugs BI 44370 (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
Most Recent Events
- 07 May 2009 New trial record